Top

Published in:

01-04-2023 | Soft Tissue Infection | News item

One lot of atovaquone recalled due to potential contamination

Published in: Reactions Weekly | Issue 1/2023

Excerpt

The US FDA has published an announcement from Camber Pharmaceuticals of a voluntary recall of one lot Atovaquone Oral Suspension 750mg/5mL due to potential contamination with Bacillus cereus. …

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product Internet Document : 31 Mar 2023. Available from: URL: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/camber-pharmaceuticals-inc-issues-voluntary-nationwide-recall-atovaquone-oral-suspension-usp

Title: One lot of atovaquone recalled due to potential contamination
Publication date: 01-04-2023
Publisher: Springer International Publishing
Keywords: Soft Tissue Infection
Endocarditis
Atovaquone
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-36781-z

2024 ASCO Annual Meeting

Springer Medicine

One lot of atovaquone recalled due to potential contamination

Excerpt

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

Covid-19-vaccine

Cefazolin/propofol/rocuronium-bromide

Antineoplastics

Multiple drugs

Ciprofloxacin

Doxycycline